Advanced Biomed Inc. (NASDAQ:ADVB) Shares Shorted: Short Interest Up 91.9% in September

Advanced Biomed Inc. (NASDAQ:ADVB) saw a significant growth in short interest in the month of September. As of September 30th, there was short interest totaling 18,897 shares, a growth of 91.9% from the September 15th total of 9,845 shares. Based on an average trading volume of 22,487 shares, the days-to-cover ratio is presently 0.8 days. Currently, 1.6% of the shares of the stock are sold short.

Analyst Ratings Changes

A number of research firms recently weighed in on ADVB. Wall Street Zen raised shares of Advanced Biomed to a “hold” rating in a report on Saturday, August 22nd. Weiss Ratings downgraded shares of Advanced Biomed from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, October 8th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Advanced Biomed Trading Down 1.5%

Shares of ADVB traded down $0.07 during trading hours on Thursday, reaching $5.07. 5,843 shares of the company’s stock traded hands, compared to its average volume of 753,835. Advanced Biomed has a 12 month low of $3.61 and a 12 month high of $24.23. The stock has a market cap of $8.37 million, a PE ratio of 1.06 and a beta of 0.01. The firm’s 50 day simple moving average is $7.65 and its 200-day simple moving average is $6.46.

Advanced Biomed (NASDAQ:ADVB) last posted its quarterly earnings data on Tuesday, October 13th. The company reported $0.44 earnings per share for the quarter.

Advanced Biomed Company Profile

Advanced Biomed Inc is a clinical-stage biopharmaceutical company focused on developing radiopharmaceutical products for the diagnosis and treatment of cancer.

The company’s research is centered on radioligand therapies, which use targeting molecules to deliver radioactive substances directly to cancer cells. Its development programs include products designed to target prostate-specific membrane antigen (PSMA), an established target in prostate cancer.

Advanced Biomed’s programs remain subject to clinical development and regulatory review.